Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1)

Journal of Internal Medicine

Volumn 243, Issue 6, 1998, Pages 447-453

  Marx, S J ^a,d   Agarwal, S K ^a   Kester, M B ^a   Heppner, C ^a   Kim, Y S ^a   Emmert Buck, M R ^b   Debelenko, L V ^b   Lubensky, I A ^b   Zhuang, Z ^b   Guru, S C ^c   Manickam, P ^c   Olufemi, S E ^c   Skarulis, M C ^a   Doppman, J L ^d   Alexander, R H ^b   Liotta, L A ^b   Collins, F S ^c   Chandrasekharappa, S C ^c   Spiegel, A M ^a   Burns, A L ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Gastrinoma; Oncogene; Parathyroid adenoma; Tumour suppressor

Indexed keywords

MENIN PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; CONFERENCE PAPER; DNA FINGERPRINTING; GENE MUTATION; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID TUMOR; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

CODON; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PARATHYROID NEOPLASMS;

EID: 7144257174     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00348.x     Document Type: Conference Paper

References (41)

1. Metz DC, Jensen RT, Bale AE, Skarulis MC, Eastman RC, Nieman L et al. Multiple endocrine neoplasia type 1: clinical features and management. In: Bilezekian JP, Levine MA & Marcus R, eds. The Parathyroids. New York: Raven Press, 1994: 591-646.
2. Friedman E, Larsson C, Amorosi A, Brandi ML, Bale AE, Metz D et al. Multiple endocrine neoplasia type 1: pathology, pathophysiology, and differential diagnosis. In: Bilezekian JP, Levine MA & Marcus R, eds. The Parathyroids. New York: Raven Press, 1994: 647-80.
3. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-7.
4. Courseaux A, Grosgeorge J, Gaudray P, Pannett AAJ, Forbes SA, Williamson C et al. Definition of the minimal MEN1 candidate area based on a 5-Mb integrated map of proximal 11q13. Genomics 1996; 37: 354-65.
5. Friedman E, Sakaguchi K, Bale AE, Falchetti A, Streeten E, Zimering MB et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med 1989; 321: 213-18.
6. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi S-E, Collins FS, Emmert-Buck MR et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997; 276: 404-7.
7. Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997; 7: 1169-75.
8. Lemmens I. Van de Ven WJM, Kas K, Zhang CX, Giraud S, Wautot V et al. Identilication of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997; 7: 1177-83.
9. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC et al. Somatic mutation of the MEN1 gene in parathyroid tumors. Nat Genet 1997; 16: 375-8.
10. Sarkar G, Yoon HS, Sommer SS. Dideoxy fingerprintiag (ddF): a rapid and efficient screen for the presence of mutations. Genomics 1992; 13: 441-3.
11. Manickam P, Guru SC, Debelenko LV, Agarwal SK, Olufemi SE, Weisemann JM et al. Eighteen new polymorphic markers in the multiple endocrine neoplasia type 1 (MEN1) region. Hum Genet 1997; 101: 102-8.
12. Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann JM et al. A transcript map of the 2.8 Mb region containing the multiple endocrine neoplasia type 1 (MEN1) locus. Genome Res 1997; 7: 725-35.
13. Hershon KS, Kelly WA, Shaw CM, Schwarte R, Bierman EL. Prolactinomas as part of the multiple endocrine neoplastic syndrome type 1. Am J Med 1983; 74: 713-20.
14. Bid ri) in four kindreds from Newfoundland. Hum Mut 1998; 11: 264-9.
15. Marx SJ, Spiegel AM, Levine MA, Rizzoli RE, Lasker RD. Santora AC II et al. Familial hypocalciuric hypercalcemia: the relation to primary parathyroid hyperplasia. N Engl J Med 1982; 307: 416-26.
16. Kassem M, Zhang X, Brask S, Eriksen EF, Mosekilde L, Kruse T. Familial isolated primary hyperparathyroidism. Clin Endocrinol 1994; 41: 415-20.
17. Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995; 56: 944-50.
18. Teh BT, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab 1996; 81: 4204-11.
19. Brown EM, Pollak M, Seidman CE, Seidman JG, Chou YHW, Riccardi D, Herbert SC. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333: 234-40.
20. Law WM Jr, Hodgson S, Heath H III. Autosomal recessive inheritance of familial hyperparathyroidism. N Engl J Med 1983; 309: 650-3.
21. Tahara H, Smith AP, Gaz RD, Cryns VL, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Canc Res 1996; 56: 599-605.
22. Beaudet AL, Tsui L. A suggested nomenclature for designating mutations. Hum Mutat 1993; 2: 245-8.
23. Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G et al. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab 1997; 82: 486-92.
24. Berezin M, Karasik A. Familial prolactinoma. Clin Endocrinol 1995; 42: 483-6.
25. Pestell RG, Alford FP, Best JD. Familial acromegaly. Acta Endocrinol (Copenh) 1989; 121: 286-9.
26. Yamada S, Yoshimoto K, Sano T, Takada K, Itakura M, Usui M, Teramoto A Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. Clin Endocrinol Metab 1997; 82: 239-42.
27. Maioli M, Ciccarese M, Pacifico A, Tonolo G, Ganau A, Cossu S et al. Familial insulinoma; description of two cases. Acta Diabetol 1992; 29: 38-40.
28. Yeatman TJ, Sharp JV, Kimura AK. Can susceptibility to carcinoid tumors be inherited? Cancer 1989; 63: 390-3.
29. Falchetti A, Bale AE, Amorosi A, Bordi C, Cicci P, Bandini S et al. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 1993; 76: 139-44.
30. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB, Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-53.
31. Dung Q, Debelenko L, Chandrasekharappa S, Emmert-Buck MR, Zhuang Z, Guru SC et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids. lipomas. and other uncommon tumors in familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1997; 82: 1416-20.
32. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbots AJ, Broome JC et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997; 82: 818-24.
33. Debelenko LV, Zhuang Z, Emmert-Buek MR, Chandrasekharappa SC, Manickam P, Guru SC et al. Allelic deletions on chromosome 11q13 in MEN 1-associated and sporadic duodenal gastrinomas and pancreatic endocrine tumors. Canc Res 1997; 157: 2238-43.
34. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S et al. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-4.
35. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-92.
36. Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997; 133: 853-7.
37. Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997; 150: 297-303.
38. Jesudasan RA, Rahman MR, Evans GA, Srivatsan ES. Reply to Popescu and Zimonjic. Am J Hum Genet 1996; 58: 424-5.
39. Marx SJ, Vinik AI, Santen RJ, Floyd JC Jr, Mills JL, Green J III. Multiple endocrine neoplasia type I. Assessment of laboratory tests to screen for the gene in a large kindred. Medicine 1986; 65: 226-41.
40. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quart J Med 1996; 89: 653-69.
41. American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors. Ethical, legal and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995; 57: 1233-41.